Identifying the genomic and clinical features of AKT1 / PIK3CA mutant metastatic prostate cancer using circulating tumour DNA
Identifying the genomic and clinical features of AKT1 / PIK3CA mutant metastatic prostate cancer using circulating tumour DNA
使用循环肿瘤 DNA 鉴定 AKT1 / PIK3CA 突变型转移性前列腺癌的基因组和临床特征
批准号：
412225
负责人：
Herberts Cameron
金额：
$0.11万
依托单位国家：
加拿大
项目类别：
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-09-01 至 2020-09-01
中文摘要
翻译
晚期前列腺癌(PCA)总是致命的。尽管有许多可用的治疗选择，但几乎没有生物标志物可以帮助将药物与最有可能受益的个别患者配对。这意味着许多患者都是终极患者。
英文摘要
Late-stage prostate cancer (PCa) is invariably lethal. Despite many available treatment options, there are few biomarkers to assist with pairing drugs to individual patients who are most likely to receive benefit. This means that many patients are ultimat
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Determining biomarkers of response to docetaxel chemotherapy in men with metastatic castration resistant prostate cancer.
-
批准号：439993
-
项目类别：Studentship Programs
-
资助金额：$7.65万
-
财政年份：2020
-
负责人：Herberts Cameron
-
依托单位：
Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer using circulating cell-free tumour DNA
-
批准号：406704
-
项目类别：Miscellaneous Programs
-
资助金额：$0.44万
-
财政年份：2019
-
负责人：Herberts Cameron
-
依托单位：
Circulating tumor DNA (ctDNA) profiling reveals a deficiency of biomarkers predictive of docetaxel response in patients with metastatic castration-resistant prostate cancer (mCRPC).
-
批准号：391726
-
项目类别：
-
资助金额：$0.08万
-
财政年份：2018
-
负责人：Herberts Cameron
-
依托单位：
Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer using circulating cell-free tumour DNA
-
批准号：406339
-
项目类别：Studentship Programs
-
资助金额：$1.27万
-
财政年份：2018
-
负责人：Herberts Cameron
-
依托单位：
海外基金
